Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Respiratory diseases 9

Respiratory Diseases

pharma-news-for-algernon-pieris-gaumard-hekka-labs

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Algernon’s NP-120 (ifenprodil); Pieris’s cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem

Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment. A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenprodil precisely acts on the NMDA-type subunit 2B (GluN2B). The agency offered the feedback at the pre-Investigational New Drug (pre-IND) meeting for the therapy. As per an announcement, the meeting proffered guidance on the Phase IIb protocol design submitted by Algernon and the endpoints, which were chosen. Moreover, the FDA sought completion of standard...

Explore More...

Pharma News

FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million

Pharma-News

Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid

PHARMA NEWS

J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug

Coronavirus (COVID- 19)

The epidemic now has a name: COVID-19

Pharma News

Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection

Digital therapeutics

Potential of Digital therapeutics and increasing CVDs

$Chronic Refractory Cough Market landscape$

Chronic Refractory Cough Market landscape: A new approach to treating cough

World COPD Day

World COPD Day

Chronic Obstructive Pulmonary Disease (COPD ) Treatment Market

Is Air Pollution a driver in COPD Treatment Market?

Pharma news

FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis

Cystic Fibrosis Drug Market

Cystic Fibrosis Drug Market: Emerging drugs that may improve lung infections

lung-day

World Lung Day

Idiopathic Pulmonary Fibrosis Market Landscape and Forecast

Idiopathic Pulmonary Fibrosis Market Landscape and Forecast

idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime

Idiopathic Pulmonary Fibrosis –Scarring For A Lifetime

WORLD NO TOBACCO DAY

Recent Pharma News

Notizia

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly